What is roseola infantum?
Roseola infantum is an infection caused by a type of herpes virus. It typically affects babies and toddlers. Other names for this health issue are sixth disease, exanthema subitum, or just “roseola.”
What does roseola look like on a child?
What does roseola look like? The rash looks like many small, flat, pink spots or patches. Sometimes the spots may be raised. You may notice a white ring around some of the spots. The rash may start on your child’s chest, back, and abdomen, and it can then spread to the neck and arms.
What is roseola and how is it treated?
Roseola is an infection that typically affects babies and toddlers. It causes a high fever that lasts for 3–5 days, then a rash for a day or two. There is no specific treatment or vaccine.
How many roseola images are available on Onoff Shutterstock?
On Off Shutterstock’s safe search will exclude restricted content from your search results roseola images 435 roseola stock photos, vectors, and illustrations are available royalty-free. See roseola stock video clips of 5 baby rash=skin disease childbaby under 2rash childrubellababy rushbaby with measlesbaby rasheschildren measleskid rash
Roseola infantum is a common disease of childhood that is seen globally and is caused by infection with human herpesvirus 6 (HHV-6), or, less frequently, by human herpesvirus 7 (HHV-7).
How do you treat roseola in babies?
Roseola symptoms typically clear up on their own in about a week as the virus runs its course. Your healthcare provider may recommend giving your child acetaminophen or ibuprofen to bring down the fever. You shouldn’t need to treat the rash because it doesn’t itch or cause pain.
How common is roseola in children?
Roseola is a very common, mild infection, usually affecting children between the ages of six months and two years. Roseola may cause a sudden, high temperature followed by a raised, red rash that lasts for a few days.
What is the prognosis of Roseola infantum (HHV6)?
Roseola infantum is a clinically diagnosed, self-limited illness that can be treated symptomatically. HHV-6 will likely remain latent in immunocompetent patients but can be a major cause of morbidity and mortality in patients who are immunosuppressed.
